» Articles » PMID: 17625570

Identification of the Transforming EML4-ALK Fusion Gene in Non-small-cell Lung Cancer

Abstract

Improvement in the clinical outcome of lung cancer is likely to be achieved by identification of the molecular events that underlie its pathogenesis. Here we show that a small inversion within chromosome 2p results in the formation of a fusion gene comprising portions of the echinoderm microtubule-associated protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC) cells. Mouse 3T3 fibroblasts forced to express this human fusion tyrosine kinase generated transformed foci in culture and subcutaneous tumours in nude mice. The EML4-ALK fusion transcript was detected in 6.7% (5 out of 75) of NSCLC patients examined; these individuals were distinct from those harbouring mutations in the epidermal growth factor receptor gene. Our data demonstrate that a subset of NSCLC patients may express a transforming fusion kinase that is a promising candidate for a therapeutic target as well as for a diagnostic molecular marker in NSCLC.

Citing Articles

Molecular Underpinnings of Brain Metastases.

Jacome M, Wu Q, Chen J, Mohamed Z, Mokhtari S, Pina Y Int J Mol Sci. 2025; 26(5).

PMID: 40076927 PMC: 11900073. DOI: 10.3390/ijms26052307.


Current Biomarkers in Non-Small Cell Lung Cancer-The Molecular Pathologist's Perspective.

Steinestel K, Arndt A Diagnostics (Basel). 2025; 15(5).

PMID: 40075878 PMC: 11899415. DOI: 10.3390/diagnostics15050631.


Ensartinib as a neoadjuvant therapy for stage IIIA non-small cell lung cancer patients with EML4-ALK fusion: a case report and literature review.

Zhang H, Xia W, Zhang Y, Bao S, Zeng J, Li X Front Oncol. 2025; 15:1474997.

PMID: 40071084 PMC: 11893432. DOI: 10.3389/fonc.2025.1474997.


ALK in cancer: from function to therapeutic targeting.

Voena C, Ambrogio C, Iannelli F, Chiarle R Nat Rev Cancer. 2025; .

PMID: 40055571 DOI: 10.1038/s41568-025-00797-9.


A novel automated IHC staining system for quality control application in ALK immunohistochemistry testing.

Hou C, Song X, Chen H, Chang C, Lu J, Li C Pathol Oncol Res. 2025; 31:1611964.

PMID: 40017673 PMC: 11864879. DOI: 10.3389/pore.2025.1611964.